iSpecimenISPC +5.53%49 Days Payable is 5,469.57 as of Mar. 2026, which is 4188% above its 10-year median of 127.55. GuruFocus rates ISPC with a GF Score™ of 49/100 and a GF Value™ of $6.72 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, iSpecimen ranks better than 94.76% on this metric.
iSpecimen's average Accounts Payable for the
three
months ended in Mar. 2026 was $5.04 Mil. iSpecimen's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.08 Mil.
Hence, iSpecimen's Days Payable for the
three
months ended in Mar. 2026 was 5,469.57.
The historical rank and industry rank for iSpecimen's Days Payable or its related term are showing as below:
ISPC'
s Days Payable Range Over the Past 10 Years
Min: 91.27 Med: 127.55 Max: 1257.33
Current: 1257.33
During the past 8 years, iSpecimen's highest Days Payable was 1257.33. The lowest was 91.27. And the median was 127.55.
ISPC's Days Payable is ranked better than 94.76% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs ISPC: 1257.33
iSpecimen's Days Payable
increased
from Mar. 2025 (553.60) to Mar. 2026 (5,469.57).
It may suggest that iSpecimendelayed paying its suppliers.
iSpecimen Days Payable Related Terms
iSpecimen Days Payable Historical Data
* Premium members only.
The historical data trend for iSpecimen's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, iSpecimen's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iSpecimen Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's Days Payable distribution charts can be found below:
* The bar in red indicates where iSpecimen's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
iSpecimen's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iSpecimen (ISPC) has a Days Payable of 5,469.57 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iSpecimen and its competitors. This is 4188% above median its historical median of 127.55. Over the past decade, iSpecimen's Days Payable has ranged from 91.27 to 1,257.33. According to the industry distribution chart, iSpecimen ranks #10 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 5.2%.
Is iSpecimen's Days Payable too high?
iSpecimen's current Days Payable of 5,469.57 is 4188% above median its 10-year median of 127.55. Over the past 10 years, this metric has ranged from a low of 91.27 to a high of 1,257.33. The Medical Diagnostics & Research industry median Days Payable is 68.87. iSpecimen's value of 5,469.57 is 7841.9% above this industry median. Based on the distribution chart, iSpecimen ranks #10 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, iSpecimen has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does iSpecimen's Days Payable compare to FUNI and IVRO?
According to the Medical Diagnostics & Research industry distribution chart, iSpecimen ranks #10 out of 191 companies for Days Payable. This places iSpecimen in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.87. iSpecimen's value of 5,469.57 is 7841.9% above this benchmark. Historically, iSpecimen's own Days Payable has ranged from 91.27 to 1,257.33 over the past decade. While the company's 10-year median is 127.55 vs. the industry median of 68.87, iSpecimen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iSpecimen's current Days Payable of 5,469.57 is 7841.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on iSpecimen and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iSpecimen's current Days Payable is 5,469.57, which is 4188% above median its own 10-year median of 127.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iSpecimen stock overvalued right now?
Based on GuruFocus' analysis, iSpecimen (ISPC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.72, compared to a current price of $2.61 — trading 61.2% below its estimated fair value. The current Days Payable is 5,469.57, which is 4188% above median its 10-year median of 127.55 and 7841.9% above the Medical Diagnostics & Research industry median of 68.87. iSpecimen's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For iSpecimen (ISPC), the current Days Payable is 5,469.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iSpecimen (ISPC) Overvalued in 2026?
Based on GuruFocus' analysis, iSpecimen stock appears to be undervalued.
The current stock price of $2.61 is trading 61.2% below its estimated GF Value™ of $6.72.
GuruFocus considers iSpecimen to be Possible Value Trap.
Key valuation signals for ISPC:
Days Payable: 5,469.57 (4188% above median its 10-year median of 127.55)
GF Value™: $6.72 vs. price of $2.61 (61.2% below fair value)
Industry Position: 7841.9% above the Medical Diagnostics & Research median (#10 of 191)
No single metric tells the full story. See the ISPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority coming from the Americas. The Company has one reportable segment: biospecimens.
49GF Score
Get the complete analysis for ISPC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISPC has been successfully added to your 
